Target intelligence / Profile preview

Plasma membrane electron transport system (PMET)

Target
PMET
Molecular classification
Other (multi-enzyme system), Enzyme (includes oxidoreductases, NADPH oxidases, quinone oxidoreductases—these are components, not the system as a whole)
01

Overview

The plasma membrane electron transport system (PMET) is a complex network of cytosolic and membrane-associated oxidoreductase enzymes embedded in the plasma membrane that transfer electrons from intracellular donors (primarily NADH and NADPH) to extracellular acceptors. This system helps maintain cellular redox homeostasis, supports metabolic processes (such as regulation of glycolytic flux in pancreatic β-cells), and provides defense against oxidative stress. Its composition varies across cell types and may involve enzymes such as NADH-cytochrome B5 oxidoreductase, NAD(P)H-quinone oxidoreductase 1 (NQO1), and NADPH oxidases (e.g., NOX2). While it plays important physiological roles, "plasma membrane electron transport system" is not a single protein or druggable target but a descriptor for a distributed, functionally related assembly of redox enzymes.

Other names
PMET systemPlasma membrane redox systemCell surface electron transport
02

Mechanism of action

Inhibitors of PMET components might block cellular redox cycling, reduce extracellular electron transfer, or alter reactive oxygen species (ROS) production.

03

Biological functions

Redox homeostasisCell proliferation and survivalCellular defenseRegulation of glycolytic flux (notably in pancreatic β-cells)Extracellular electron transfer
04

Disease associations

Cancer (altered redox control)Diabetes (β-cell function/insulin secretion)Inflammation (due to NOX family involvement)Neurodegenerative disease (oxidative stress, less direct)Other (oxidative stress–related disorders)
05

Safety considerations

Broad inhibition of PMET or redox-active enzymes could disrupt essential cellular homeostasis and antioxidant defense, leading to cellular damage or impaired cell viability.Non-specific targeting may affect multiple cell types and cause off-target toxicity
06

Interacting drugs

No specific drugs target "plasma membrane electron transport system" as a whole. Some drugs or inhibitors may act on components (e.g., NOX inhibitors, NQO1 inhibitors), but these are directed at individual enzymes within the broader system.
07

Biomarkers

No established biomarkers for PMET as a wholeSome component enzymes (e.g., NQO1) may serve as biomarkers in cancer and other diseases, but not for the system in aggregate

Beyond the preview

Go deeper on Plasma membrane electron transport system (PMET).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plasma membrane electron transport system (PMET).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call